Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Declines By 36.9%
by Danessa Lincoln · The Markets DailyBolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 30th, there was short interest totaling 1,603 shares, a drop of 36.9% from the January 15th total of 2,541 shares. Based on an average daily volume of 22,976 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company’s shares are short sold. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 22,976 shares, the short-interest ratio is presently 0.1 days.
Bolt Biotherapeutics Trading Up 0.6%
Shares of NASDAQ:BOLT traded up $0.03 during mid-day trading on Friday, reaching $4.95. 21,991 shares of the company were exchanged, compared to its average volume of 27,735. Bolt Biotherapeutics has a 1 year low of $4.41 and a 1 year high of $10.50. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.57 and a quick ratio of 3.57. The firm’s 50-day simple moving average is $5.75 and its 200 day simple moving average is $5.47. The firm has a market cap of $9.50 million, a price-to-earnings ratio of -0.22 and a beta of 0.92.
Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($3.72) EPS for the quarter, topping analysts’ consensus estimates of ($5.07) by $1.35. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $0.82 million. Equities research analysts forecast that Bolt Biotherapeutics will post -1.61 EPS for the current year.
Institutional Trading of Bolt Biotherapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of BOLT. Renaissance Technologies LLC boosted its stake in shares of Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after purchasing an additional 26,400 shares during the period. T3 Companies LLC purchased a new position in Bolt Biotherapeutics in the fourth quarter valued at $208,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Bolt Biotherapeutics during the 4th quarter worth $112,000. Susquehanna International Group LLP acquired a new position in Bolt Biotherapeutics during the 3rd quarter worth $89,000. Finally, Shay Capital LLC purchased a new stake in Bolt Biotherapeutics during the 3rd quarter worth about $85,000. 86.70% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. Zacks Research cut shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, January 21st. Finally, HC Wainwright set a $7.00 target price on Bolt Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, October 20th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $34.00.
Check Out Our Latest Stock Analysis on BOLT
Bolt Biotherapeutics Company Profile
Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.